PSMD1 and infection: In summary, recombinant virus rPRV-PEDV S1 was generated by homologous recombination and the CRISPR/Cas9 system, and further evaluated for its biological characteristics in vitro and immunogenicity in pigs, which indicated that rPRV-PEDV S1 was a promising multivalent genetic engineering vaccine candidate to control PEDV and PRV variant infection.